The latest challenge for Biopharmaceuticals

The latest challenge for the biopharma industry: revisiting R&D operating models

Posted 18 June 2019

In an industry where product development is very lengthy due to strict regulations - while millions of patients are waiting for new treatments - the need for reduced time-to-market is high.

That is why Life Sciences companies will need to revisit their R&D Operating Models.

Both regulators and companies are therefore setting course towards increased agility. This has already resulted in a market where the product range is expanding from small molecules to a vast spectrum of biomolecular therapies and personalized medicines. 

A recent article by Berggren et al. (2018) states that the most successful pharma players will be those that are able to deploy analytical capabilities and that are implementing an R&D operating model that permits redirecting the focus on therapeutic areas, disease pathways, etc.

To implement such a model, an agile organization structure is needed, moving away from the traditional silos based on therapeutic areas and making room for more cross-functional R&D organizations. This also means reprioritizing projects and trials based on interim analyses and - as result thereof - the reshuffling of resources across projects. 

Source: R&D in the 'age of agile' - McKinsey & Company

At Modis, we also believe in agile portfolio management. With a big pool of experienced consultants at hand, we can aid pharma and biotech companies in assessing their portfolio management maturity and in setting up processes and tools for resources management. 

Interested in our expertise in this field?

Please do not hesitate to get in touch with us!

Get in touch